🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Superbugs are bacteria that no longer respond to antibiotics, and they’re one of the fastest-growing threats in modern healthcare. At Recce, we’re developing new anti-infectives designed to stay effective as resistance grows. #ReccePharma #AntimicrobialResistance #Superbugs

MST Access publishes update note on Recce Pharmaceuticals (RCE.AX) Read the full report here: bit.ly/4k5bLRC

📰 Reading Alert: The overuse and misuse of #antibiotics in livestock has contributed significantly to the emergence of #antimicrobialresistance, which renders antibiotics ineffective. cosmosmagazine.com/news/antibioti…

Over 19 million people in #Indonesia live with #diabetes. #Diabeticfootinfections are a serious complication, often resistant to current antibiotics and hard to treat. We’re conducting a Phase 3 clinical trial of R327 Topical Gel to help address this growing need.

Most antibiotics target one part of bacteria, like a key in a lock. If that lock mutates, they fail. R327 is different: synthetic, broad, and built to bind multiple targets. That’s how it stays ahead of resistance. #ReccePharma #R327 #AMR #Superbugs #InfectiousDiseases

Recce is building more than a product, we’re advancing a clinical pipeline designed to fight infectious diseases where current treatments fail.

Synthetic anti-infectives, designed to bypass bacterial resistance. Our approach: 🔹Synthetic compounds 🔹Unique mechanism of action 🔹Scalable manufacturing 🔹Broad-spectrum efficacy From molecule to medicine, we’re bridging science and clinical need. #R327 #AMR #ReccePharma

The threat is growing. Without effective anti-infectives, routine infections can turn deadly.

They’re called the ESKAPE pathogens, six bacteria that cause most hospital-acquired infections and resist many antibiotics. They don’t just infect. They adapt. And they’re one of the biggest reasons antimicrobial resistance is rising fast. #AMR #ESKAPEPathogens #GlobalHealth

Did you know? Most of the antibiotics we use today were discovered before the 1980s. Bacteria have changed since then. Our medicines? Not so much. With resistance on the rise, we’re relying on old tools for a growing problem. We need innovation, urgently. #R327 #AMR #Superbugs

When infections move quickly, every minute matters. R327 is designed to act fast, disrupting bacterial energy production within minutes of contact. That means faster control of serious infections and a smarter response to resistance.

Some wounds do more than hurt, especially when resistant bacteria are involved. That’s why Recce developed R327G, a topical anti-infective targeting: 🔹 Diabetic foot infections 🔹 Burn wounds 🔹 Skin and soft tissue infections

What is a diabetic foot infection? It’s one of the most common and serious complications of diabetes. When foot ulcers become infected, they can take much longer to heal and may lead to major complications. Raising awareness is the first step.

Not all infections start deep inside the body. Some begin on the surface and can become dangerous if they spread or overwhelm the body’s defenses. That’s why treating topical infections early and effectively is so important. #TopicalInfections #WoundCare #AntiInfectives

Some of the most dangerous infections start where we least expect them, on the surface. R327G is being developed to treat serious topical infections, from diabetic foot infections to burns. With strong clinical results, it's designed to act fast and fight resistance where it

Serious infections aren’t just clinical challenges. They affect lives, routines, and recovery. At Recce, we’ve designed anti-infectives that act fast and overcome resistance, because every day of delayed healing matters. #WoundCare #DFI #Superbugs #AMR #ReccePharma

Antibiotics make routine procedures safer, from C-sections to joint replacements. But antibiotic resistance is rising. Infections are lasting longer, costing more, and getting harder to treat.

Most antibiotics are discovered in nature, but nature has limits. Recce’s anti-infectives are fully synthetic, fast-acting, broad-spectrum, and designed to beat resistance. Innovation starts at the molecular level. #SyntheticAntibiotics #ReccePharma #AMR #Superbugs

From lab to life, here’s how clinical trials work. Every new treatment must go through a series of rigorous stages to prove its safety and effectiveness. Here’s a breakdown of how it works and where Recce’s programs currently stand.

Drug‑resistant infections aren’t just a health threat; they come with a massive hidden cost. Swipe to see how resistance is impacting the healthcare system.